 Catalyst Biosciences Inc NASDAQ: CBIO shares are trading higher by 180.26 at 1.06 after the company announced it sold its complement portfolio for 60 million. A definitive asset purchase and sale agreement with Vertex Pharmaceuticals Incorporated NASDAQ: VRTX has allowed Vertex to acquire. 